Warning Letter — Shoolin Pharma Chem LLP
The FDA issued a Warning Letter to Shoolin Pharma Chem LLP following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates the letter was issued on August 18, 2026, though specific regulatory violations are not detailed in the excerpt.
This affects Shoolin Pharma Chem LLP, as well as pharmaceutical manufacturers and quality departments utilizing their chemical or pharmaceutical products in their supply chain.
A Warning Letter from CDER typically indicates significant deviations from current Good Manufacturing Practice (cGMP). For regulatory professionals, this suggests potential risks to the supply chain and may necessitate an evaluation of the firm's status as a qualified supplier. While the specific nature of the violations is not provided in the source, such actions often precede import alerts or further enforcement if deficiencies are not remediated.
Review API supplier qualification programs and ensure current Good Manufacturing Practice (cGMP) compliance documentation is up to date for this entity. Quality units should consider conducting a risk assessment of any materials sourced from this facility to determine if additional testing or vendor audits are required.
FDA Warning Letter issued to: Shoolin Pharma Chem LLP. 08/18/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shoolin-pharma-chem-llp-734100-08182026
Open in openFDA / FDA.gov